1374007-10-9Relevant academic research and scientific papers
MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED THERETO
-
Page/Page column 4; 26; 29, (2013/05/21)
This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I
Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: Synthesis, structure-activity relationships, and pharmacokinetics
Ndungu, J. Maina,Krumm, Stefanie A.,Yan, Dan,Arrendale, Richard F.,Reddy, G. Prabhakar,Evers, Taylor,Howard, Randy,Natchus, Michael G.,Saindane, Manohar T.,Liotta, Dennis C.,Plemper, Richard K.,Snyder, James P.,Sun, Aiming
experimental part, p. 4220 - 4230 (2012/06/30)
The measles virus (MeV), a member of the paramyxovirus family, is an important cause of pediatric morbidity and mortality worldwide. In an effort to provide therapeutic treatments for improved measles management, we previously identified a small, non-nucl
